FindTrial
Sign In

CISPLATINO SANDOZ

DRUG5 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, Humanitas Mirasole S.p.A., Universita' Degli Studi Di Torino

Conditions

AdvancedMerkel cell carcinomasRecurrent Metastatic Nasopharingeal Carcinomalocally advanced cervical carcinomamalignant pleural effusionnaïvenon-small cell lung cancer

Phase 2

Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial
RecruitingCTIS2022-502253-34-00
Fondazione IRCCS Istituto Nazionale Dei Tumorinon-small cell lung cancer
Start: 2023-09-11Target: 26Updated: 2023-05-02
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).
RecruitingCTIS2022-500988-12-00
Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei TumoriAdvanced, naïve, Merkel cell carcinomas
Start: 2023-12-18Target: 35Updated: 2024-05-24
Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL
Not yet recruitingCTIS2025-521839-36-00
Fondazione IRCCS Istituto Nazionale Dei Tumorilocally advanced cervical carcinoma
Target: 29Updated: 2026-02-06

Phase 3

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population
Not yet recruitingCTIS2025-522472-85-00
Humanitas Mirasole S.p.A.Recurrent Metastatic Nasopharingeal Carcinoma
Target: 49Updated: 2026-01-08
Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) and Pleurectomy in the local treatment of pleural tumors. A Prospective Randomized Study The Tic-Tac Trial
WithdrawnCTIS2026-526109-13-00
Universita' Degli Studi Di Torinomalignant pleural effusion
Target: 64Updated: 2026-08-20